G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
- Sponsor
- Navy General Hospital, Beijing
- Study ID
- NCT06665217
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 14 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy — DRUGPatients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy.
Study Details
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.
Key Dates
- Start date
- Sep 24, 2025
- Status verified
- Aug 2025
- Primary completion
- Jan 31, 2029
- Completion
- Jan 31, 2030
Study Design
- Enrollment
- 80 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Induction TherapyPatients were treated by G-Pola-ZLP as Induction Therapy
Primary Outcome Measure
Overall Response Rate (ORR) [ Time Frame: 1 year ]
Central Contacts
- Liren Qian, PhD+861066947194
- Liren Qian, PhD
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLPHASE2 · Recruiting · New York Medical College · Valhalla, New York
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaPHASE1/PHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Evaluation of Human Immune Responses Vaccination in Patients With LymphomaRecruiting · Emory University · Atlanta, Georgia